文献速递心境障碍

CaMKK2作为双相障碍新兴治疗靶点

CaMKK2 as an emerging treatment target for bipolar disorder.
PubMed 文献 · Mol Psychiatry · 2023-09-20

当前双相障碍药物治疗效果有限且副作用负担重,缺乏验证靶点。综述汇总多条汇聚证据:CaMKK2在脑神经元富集,调控能量代谢与高级功能;人类CAMKK2功能缺失多态性和罕见错义突变与双相障碍相关;小鼠Camkk2基因缺失产生双相样行为,锂可改善。支持靶向CaMKK2作为双相障碍新治疗策略。

要点

  • CaMKK2是脑内富集的能量代谢与神经元功能调节激酶。
  • 人类CAMKK2功能缺失多态性和罕见错义突变与双相障碍相关。
  • 小鼠Camkk2缺失致双相样行为,锂可改善并增加CaMKK2活性。

核心结论

  • 多条汇聚证据支持将CaMKK2作为双相障碍的新治疗靶点。

研究设计与样本

  • 综述,汇总人类遗传学关联与小鼠基因敲除行为学及锂干预证据。

主要发现

  • CaMKK2在脑神经元高度富集,调控能量代谢及长时记忆、心境等高级功能。
  • 人类CAMKK2功能缺失多态性和罕见错义突变与双相障碍相关。
  • 小鼠Camkk2基因缺失引起类似患者的双相样行为,锂可改善并增加CaMKK2活性。

临床怎么用

  • 为双相障碍药物开发提供新靶点方向,提示CaMKK2活性调节可能改善心境不稳。

局限性

  • 现有证据主要来自遗传关联与动物模型,尚需临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current pharmacological treatments for bipolar disorder are inadequate and based on serendipitously discovered drugs often with limited efficacy, burdensome side-effects, and unclear mechanisms of action. Advances in drug development for the treatment of bipolar disorder remain incremental and have come largely from repurposing drugs used for other psychiatric conditions, a strategy that has failed to find truly revolutionary therapies, as it does not target the mood instability that characterises the condition. The lack of therapeutic innovation in the bipolar disorder field is largely due to a poor understanding of the underlying disease mechanisms and the consequent absence of validated drug targets. A compelling new treatment target is the Ca2+-calmodulin dependent protein kinase kinase-2 (CaMKK2) enzyme. CaMKK2 is highly enriched in brain neurons and regulates energy metabolism and neuronal processes that underpin higher order functions such as long-term memory, mood, and other affective functions. Loss-of-function polymorphisms and a rare missense mutation in human CAMKK2 are associated with bipolar disorder, and genetic deletion of Camkk2 in mice causes bipolar-like behaviours similar to those in patients. Furthermore, these behaviours are ameliorated by lithium, which increases CaMKK2 activity. In this review, we discuss multiple convergent lines of evidence that support targeting of CaMKK2 as a new treatment strategy for bipolar disorder.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kaiser J, Nay K, Horne CR, et al. CaMKK2 as an emerging treatment target for bipolar disorder. Mol Psychiatry. 2023. PMID: 37730845. doi:10.1038/s41380-023-02260-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。